BCM
XLRN

BlueCrest Capital Management’s Acceleron Pharma XLRN Stock Holding History

BlueCrest Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,665
Closed -$496K – 1595
2018
Q3 		$496K Buy
+8,665
New +$426K 0.01% 757

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlueCrest Capital Management's XLRN Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2018, closing a stake of 8,665 shares — an estimated $496K sold.

BlueCrest Capital Management first reported a position in XLRN in Q3 2018 and held it in 1 quarter. The position peaked at $496K in Q3 2018. 162 funds tracked by Wall St. Rank hold XLRN as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Acceleron Pharma position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 8,665 Acceleron Pharma shares in Q4 2018, an estimated $496K.
  • BlueCrest Capital Management first reported a position in Acceleron Pharma in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Acceleron Pharma position peaked at $496K in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.